In recent years, the debate over net price transparency (NPT) has intensified with organisations leading calls for greater transparency of net prices in the pharmaceutical sector. In a study funded by Merck Sharp & Dohme, an expert panel coordinated by CRA developed evidence on the impact of greater NPT on innovative medicines in Europe.
Drug pricing rules and tariffs reshape transfer pricing for IP
In the article “Drug Pricing Rules and Tariffs Reshape Transfer Pricing for IP,” published in Bloomberg Tax, CRA’s Transfer Pricing experts Robin Hart and ...